Roche Holding AG (RHHBY)
OTCMKTS: RHHBY · Delayed Price · USD
30.25
+0.23 (0.77%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Roche Holding AG Revenue
In the year 2023, Roche Holding AG had annual revenue of 60.44B CHF, a decrease of -8.16%.
Revenue (ttm)
60.44B CHF
Revenue Growth
-8.16%
P/S Ratio
2.94
Revenue / Employee
583,379 CHF
Employees
103,605
Market Cap
194.07B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
Dec 31, 2022 | 65.81B | 3.01B | 4.80% |
Dec 31, 2021 | 62.80B | 4.48B | 7.68% |
Dec 31, 2020 | 58.32B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRHHBY News
- 3 days ago - Vividion Therapeutics and Roche Jointly Publish Landmark Nature Paper on Clinical-Stage Covalent Allosteric Inhibitor of Werner Helicase (WRN) - Business Wire
- 4 days ago - Roche prepares for business after boom from COVID-related products - Market Watch
- 4 days ago - Swiss pharma giant Roche's first-quarter sales edge higher as its emerges from post-Covid-19 slump - CNBC
- 4 days ago - Roche Q1 sales down 6% on forex effect, loss of COVID revenue - Reuters
- 4 days ago - [Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19 - GlobeNewsWire
- 9 days ago - FDA approves Roche's Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer - GlobeNewsWire
- 9 days ago - FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer - Business Wire
- 11 days ago - Genentech's Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS - Business Wire